<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822315</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12180 REFLATE TB</org_study_id>
    <nct_id>NCT00822315</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</brief_title>
  <official_title>Phase II Open-label Randomized Multicenter Trial to Compare the Efficacy and Safety of Two Different Doses of Raltegravir and Efavirenz, All in Combination With Tenofovir and Lamivudine, in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Raltegravir is a potent antiretroviral agent that could be used as an alternative to
      efavirenz in HIV-1 infected patients with tuberculosis. However due to pharmacokinetic
      interactions, the optimal dose of raltegravir to be used in combination with rifampin is
      currently unknown.

      This phase II open-label randomized multicenter trial is designed to estimate the antiviral
      efficacy of two doses of raltegravir and one dose of efavirenz at week 24, in HIV-1 naive
      patients co-infected with active tuberculosis (TB) treated with rifampin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic success, using Time to Loss of Virologic Response (TLOVR) algorithm: -Plasma HIV RNA below 50 copies/ml at week 20, confirmed at week 24 -Absence of permanent treatment discontinuation -Absence of death -Still follow-up at week 24</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with virologic response with the following definitions: - Plasma HIV RNA &lt;50 copies/ml at week 24 - Rate of strategy discontinuation and treatment changes - Proportion of death - Proportion of patients loss to follow-up</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with virologic response with the following definitions: o Plasma HIV RNA &lt;50 copies/ml o Plasma HIV RNA &lt;400 copies/ml</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution in HIV RNA and HIV DNA (total and 2 LTR circular) from baseline to week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of viral resistance mutations in the plasma at the time of virologic failure and in comparison with HIV-RNA mutations at W0</measure>
    <time_frame>At the time of virologic failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of CD4 cell counts from baseline to week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to a new AIDS-defining event or death</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type, time to grade 3 or 4 adverse event</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of success of TB treatment</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-TB resistance rate</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of raltegravir and efavirenz trough concentration</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>raltegravir 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>raltegravir 800 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (at least 18 years old)

          -  Plasma HIV RNA &gt; 1000 copies/ml

          -  HIV-1-infection confirmed by ELISA and Western blot or Immunofluorescence

          -  ART naïve patients or

          -  ART for less than 3 months and more than 6 months ago ; an HIV resistance genotype at
             baseline showing no mutation to NNRTI and TDF or 3TC will be required

          -  For women of childbearing age, negative urinary test for pregnancy and to accept
             contraceptive methods: condom use and intra-uterine device when possible or declare no
             wish of pregnancy in the coming year.

          -  Confirmed or probable TB

          -  TB treatment including rifampin started since 2 to 8 weeks before randomisation

          -  Signed informed consent form

          -  For French patients, to be affiliated to the National Health Care System

        Exclusion Criteria:

          -  HIV-2 infection (single or with HIV-1)

          -  Woman who is pregnant or likely to become so, is breastfeeding or refuses to use
             contraception

          -  ALT&gt;2.5N, Hb &lt;7g/dl, neutrophils &lt; 750/mm3, platelet&lt;50 000/mm3, bilirubin &gt;5N, lipase
             &gt;3N

          -  Creatinine clearance &lt;60ml/min as assessed by the Cockcroft method

          -  Ongoing psychiatric pathology or any condition (including, but not limited to, the
             consumption of alcohol or drugs) which might, in the investigator's opinion,
             compromise the safety of treatment and/or patient compliance with the protocol

          -  Concomitant treatments including phenytoin or phenobarbital (compounds interacting
             with UGT1A1)

          -  Prior TB with a Mycobacterium tuberculosis strain resistant to rifampin

          -  TB treatment started for more than 8 weeks before randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatriz Grinsztejn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fiocruz, Rio de Janiero, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Michel Molina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Saint-Louis, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Genral de Nova Iguaçu</name>
      <address>
        <city>Nova Iguaçu</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Coceiçao</name>
      <address>
        <city>Porto alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sanatorio Pertenon</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipec/Fiocruz</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitral Universitario Pr Edgar Santos</name>
      <address>
        <city>Salvador da Bahia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STD/AIDS department</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Villeneuve Saint Georges</name>
      <address>
        <city>Villeneuve Saint Georges</city>
        <zip>94195</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2009</study_first_submitted>
  <study_first_submitted_qc>January 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2009</study_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>France</keyword>
  <keyword>Brazil</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

